Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eagle Pharmaceuticals, Inc. - Common Stock (NQ: EGRX )

2.140 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eagle Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Eagle Pharmaceuticals, Inc. on Behalf of Eagle Pharmaceuticals Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Lowey Dannenberg, P.C. is Investigating Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) for Potential Violations of the Federal Securities Laws
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Eagle Pharmaceuticals, Inc. (EGRX)
From Kirby McInerney LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – EGRX
From Rosen Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Present at September Healthcare Conferences
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Reports Second Quarter 2021 Results
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference
From Eagle Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.